scispace - formally typeset
Open AccessJournal ArticleDOI

Artemisinin Resistance in Plasmodium falciparum Malaria

Reads0
Chats0
TLDR
The overall median clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours in Wang Pha (P<0.001) in each of the two locations as discussed by the authors.
Abstract
We studied 40 patients in each of the two locations. The overall median parasite clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours (interquartile range, 36 to 66) in Wang Pha (P<0.001). Recrudescence confirmed by means of polymerase-chain-reaction assay occurred in 6 of 20 patients (30%) receiving artesunate monotherapy and 1 of 20 (5%) receiving artesunate–mefloquine therapy in Pailin, as compared with 2 of 20 (10%) and 1 of 20 (5%), respectively, in Wang Pha (P = 0. 31). These markedly different parasitologic responses were not explained by differences in age, artesunate or dihydroartemisinin pharmacokinetics, results of isotopic in vitro sensitivity tests, or putative molecular correlates of P. falciparum drug resistance (mutations or amplifications of the gene encoding a multidrug resistance protein [PfMDR1] or mutations in the gene encoding sarco–endoplasmic reticulum calcium ATPase6 [PfSERCA]). Adverse events were mild and did not differ significantly between the two treatment groups. CONCLUSIONS P. falciparum has reduced in vivo susceptibility to artesunate in western Cambodia as compared with northwestern Thailand. Resistance is characterized by slow parasite clearance in vivo without corresponding reductions on conventional in vitro susceptibility testing. Containment measures are urgently needed. (ClinicalTrials.gov number, NCT00493363, and Current Controlled Trials number, ISRCTN64835265.)

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?

TL;DR: Functional in vitro assays such as the growth/invasion inhibition assays (GIA) are widely used, but it is unclear whether GIA activity correlates with protection or predicts vaccine efficacy, and more work is needed to establish the utility of GIA for blood-stage vaccine development.
Journal ArticleDOI

Surveillance of Artemisinin Resistance in Plasmodium falciparum in India Using the kelch13 Molecular Marker

TL;DR: This is the first report of Pfk-13 point mutations from India, and nonsynonymous mutations in the propeller region were found in four patients from the northeastern states, but their presence did not correlate with ACT treatment failures.
Journal ArticleDOI

Isoprenoid Metabolism in Apicomplexan Parasites

TL;DR: Recent work identifying the first methylerythritol phosphate pathway regulator in apicomplexan parasites is described, and several promising areas for ongoing research into this well-validated antiparasitic target are introduced.
Journal ArticleDOI

Expanding the Antimalarial Drug Arsenal-Now, But How?

TL;DR: An overview of antimalarial drug resistance, associated parasite genetic factors, Emergence of artemisinin resistance in P. falciparum, and the antimalari drug development pipeline is provided to highlight some examples of the aforementioned approaches to future antimalaria treatment.
Journal ArticleDOI

Phenotypic Changes in Artemisinin-Resistant Plasmodium falciparum Lines In Vitro: Evidence for Decreased Sensitivity to Dormancy and Growth Inhibition

TL;DR: In this paper, the authors investigated the link between dormancy and resistance, using artelinic acid (AL)-resistant parasites, and demonstrated that the AL resistance phenotype has decreased sensitivity of mature-stage parasites, decreased sensitivity to the induction of dormancy, and a faster recovery from dormancy.
References
More filters
Journal ArticleDOI

Evidence of Artemisinin-Resistant Malaria in Western Cambodia

TL;DR: Artemisinins are potent and rapidly acting antimalarial drugs, and their widespread use for treating patients with Plasmodium falciparum malaria raises the question of emerging drug resistance.
Journal ArticleDOI

Artemisinins target the SERCA of Plasmodium falciparum

TL;DR: It is shown that artemisinins, but not quinine or chloroquine, inhibit the SERCA orthologue (PfATP6) of Plasmodium falciparum in Xenopus oocytes with similar potency to thapsigargin (another sesquiterpene lactone and highly specific SERCA inhibitor).
Journal ArticleDOI

Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.

TL;DR: Artesunate should become the treatment of choice for severe falciparum malaria in adults because it is more rapidly acting than intravenous quinine in terms of parasite clearance and is simpler to administer.
Journal ArticleDOI

Qinghaosu (artemisinin): the price of success.

TL;DR: Artemisinin combination treatments are now first-line drugs for uncomplicated falciparum malaria, but access to ACTs is still limited in most malaria-endemic countries and a global subsidy would make these drugs more affordable and available.
Related Papers (5)

Spread of Artemisinin Resistance in Plasmodium falciparum Malaria

Elizabeth A. Ashley, +82 more